title: Role of lamivudine in the posttransplant prophylaxis of chronic hepatitis B virus and hepatitis delta virus coinfection.
abstract: BACKGROUND
  Posttransplant combined lamivudine (LAM) and immunoglobulin (HBIg) prophylaxis is the gold standard in the case of single hepatitis B virus (HBV), but is still not recommended in the case of patients coinfected with hepatitis delta virus (HDV).
  
  
  METHODS
  We compared two consecutive groups of chronic HDV carriers who survived >6 months after liver transplantation of the risk of recurrence, survival and HBIg requirements: 21 received passive prophylaxis (HBIg group) and 25 were treated with combined prophylaxis (LAM+HBIg group). The immunoprophylaxis schedule was the same in both groups: intramuscular HBIg targeted to maintain anti-HBs levels of >500 IU/L during the first 6 posttransplant months and >200 IU/L thereafter.
  
  
  RESULTS
  The mean length of follow-up in the two groups was significantly different (133 vs. 40 months; P<0.001). None of the patients in either group developed recurrent hepatitis, and the 3-year actuarial survival rate was 100% in both groups. During the first 6 months, HBIg requirement was 38% lower in the LAM+HBIg group although similar anti-HBs target levels were maintained, leading to significantly lower costs (5,000 Euros in the first year and 500 Euros in the second).
  
  
  CONCLUSIONS
  This is the first study of large and homogeneous cohort of long-term HDV coinfected liver transplant survivors showing the absence of HBV recurrence under combined prophylaxis. Although retrospective, our results suggest that combined anti-HBV prophylaxis should also be preferred to single immunoprophylaxis in patients with HDV coinfection because it allows significant cost savings in the first two posttransplant years.
authors.affiliation: UO Trapianto Fegato e Polmone, Fondazione IRCCS Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milan, Italy. lucio.caccamo@libero.it
authors.forename: Lucio
authors.initials: L
authors.lastname: Caccamo
authors.forename: Francesca
authors.initials: F
authors.lastname: Agnelli
authors.forename: Paolo
authors.initials: P
authors.lastname: Reggiani
authors.forename: Umberto
authors.initials: U
authors.lastname: Maggi
authors.forename: M Francesca
authors.initials: MF
authors.lastname: Donato
authors.forename: Stefano
authors.initials: S
authors.lastname: Gatti
authors.forename: Giovanni
authors.initials: G
authors.lastname: Paone
authors.forename: Ernesto
authors.initials: E
authors.lastname: Melada
authors.forename: Giorgio
authors.initials: G
authors.lastname: Rossi
mesh_terms: D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology; D005260:Female; D019694:Hepatitis B, Chronic / Q000150:complications / Q000517:prevention & control*; D003699:Hepatitis D / Q000150:complications / Q000517:prevention & control*; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000453:epidemiology; D016031:Liver Transplantation / Q000009:adverse effects* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology; D012086:Reoperation; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D016019:Survival Analysis
chemical_list: D007136:Immunoglobulins; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; C045213:hepatitis B hyperimmune globulin